ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2012
Imatinib mesylate improves liver regeneration and attenuates liver fibrogenesis in CCL4-treated mice.
Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- ABL1‒YAP1 axis in intestinal stem cell activated by deoxycholic acid contributes to hepatic steatosis.Journal of translational medicine · 2024Article
- Use of a pH-responsive imatinib mesylate sustained-release hydrogel for the treatment of tendon adhesion by inhibiting PDGFRβ/CLDN1 pathway.Bioactive materials · 2024Article
- The Role of Mesenchymal Stem Cells and Imatinib in the Process of Liver Fibrosis Healing ThroughReports of biochemistry & molecular biology · 2023Article
- Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment.Frontiers in medicine · 2021Review
- Effects of Combined Admistration of Imatinib and Sorafenib in a Murine Model of Liver Fibrosis.Molecules (Basel, Switzerland) · 2020Article
- Imatinib mesylate use in refractory eosinophilic granulomatosis with polyangiitis: a literature review and a case report.Clinical rheumatology · 2018Review
- PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review).Molecular medicine reports · 2017Review
- Intestinal fibrosis: ready to be reversed.Current opinion in gastroenterology · 2017Review
- Imatinib accelerates progenitor cell-mediated liver regeneration in choline-deficient ethionine-supplemented diet-fed mice.International journal of experimental pathology · 2016Article
- Review
- Delivery and targeting of miRNAs for treating liver fibrosis.Pharmaceutical research · 2015Review
- Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step.Frontiers in pharmacology · 2015Review
- New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials.Frontiers in pharmacology · 2015Review
- Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats.Journal of gastroenterology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsImatinib mesylate (STI-571), a tyrosine kinase inhibitor, has previously been demonstrated to attenuate liver fibrogenesis through inhibition of the activation of hepatic stellate cells (HSCs) in CCL(4)-treated rat models.
aimsThis study aimed to further evaluate the role of STI-571 in liver regeneration. MATERIALS AND
methodsAll animals were divided into four groups, and mice were treated with or without CCL(4) and STI-571 (n = 6 for each group).
resultsActivated cultured HSCs in vitro with STI-571 administration showed increased apoptosis and reduced proliferation, as determined by flow cytometric analysis, 3-(4, 5-cimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide assay, and confocal microscopy. STI-571 treatment attenuated liver fibrosis in vivo, as was evident in the results of histology, mRNA level, and expression analysis of smooth muscle actin and type I collagen. Mice treated with STI-571 had increased liver weight ratio and the improvement in liver regeneration was compatible with the change of serum interleukin 6 levels (p < 0.05). Further, increased apoptosis and a reduced proliferation were observed in the CCL(4)-treated mice after STI-571 treatment based on the immunohistochemical staining of Annexin V, phosphorylated STAT3, and PCNA.
conclusionSTI-571 treatment effectively attenuated liver fibrogenesis and improved in liver regeneration in vivo and induced apoptosis in HSCs both in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.